FI4010082T4 - Multispesifisiä vaihtelevan tcr-deltaketjun 1 vastaisia vasta-aineita - Google Patents

Multispesifisiä vaihtelevan tcr-deltaketjun 1 vastaisia vasta-aineita

Info

Publication number
FI4010082T4
FI4010082T4 FIEP21756070.5T FI21756070T FI4010082T4 FI 4010082 T4 FI4010082 T4 FI 4010082T4 FI 21756070 T FI21756070 T FI 21756070T FI 4010082 T4 FI4010082 T4 FI 4010082T4
Authority
FI
Finland
Prior art keywords
fragment
epitope
multispecific antibody
antibody
multispecific
Prior art date
Application number
FIEP21756070.5T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI4010082T3 (fi
Inventor
Mark Uden
Mihriban Tuna
Natalie Mount
Robert Good
Joshua Freedman
Shefali Bhumbra
Oliver Nussbaumer
Raj Jaysukhlal Mehta
Original Assignee
Gammadelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4010082(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd
Application granted granted Critical
Publication of FI4010082T3 publication Critical patent/FI4010082T3/fi
Publication of FI4010082T4 publication Critical patent/FI4010082T4/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
FIEP21756070.5T 2020-08-14 2021-08-14 Multispesifisiä vaihtelevan tcr-deltaketjun 1 vastaisia vasta-aineita FI4010082T4 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (2)

Publication Number Publication Date
FI4010082T3 FI4010082T3 (fi) 2023-04-04
FI4010082T4 true FI4010082T4 (fi) 2026-03-24

Family

ID=80247426

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP21756070.5T FI4010082T4 (fi) 2020-08-14 2021-08-14 Multispesifisiä vaihtelevan tcr-deltaketjun 1 vastaisia vasta-aineita
FIEP23187269.8T FI4269444T3 (fi) 2020-08-14 2021-08-14 Multispesifisiä anti-tcr-delta-variaabeli 1 -vasta-aineita

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP23187269.8T FI4269444T3 (fi) 2020-08-14 2021-08-14 Multispesifisiä anti-tcr-delta-variaabeli 1 -vasta-aineita

Country Status (18)

Country Link
EP (7) EP4265642B1 (https=)
JP (1) JP7847579B2 (https=)
KR (1) KR20230083267A (https=)
CN (1) CN116209456A (https=)
AU (1) AU2021323512A1 (https=)
BR (1) BR112023002741A2 (https=)
CA (1) CA3188682A1 (https=)
CO (1) CO2023003009A2 (https=)
DK (2) DK4010082T4 (https=)
ES (2) ES2943063T3 (https=)
FI (2) FI4010082T4 (https=)
IL (1) IL300517A (https=)
LT (2) LT4010082T (https=)
MX (1) MX2023001728A (https=)
PL (2) PL4269444T3 (https=)
PT (2) PT4010082T (https=)
SI (2) SI4010082T1 (https=)
WO (1) WO2022034562A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
WO2023250485A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. Assay for t cell dependent multispecific compounds
WO2024193459A1 (en) * 2023-03-17 2024-09-26 Nanjing Legend Biotech Co., Ltd. METHODS OF CULTURING Vδ1 T CELLS
WO2025147597A1 (en) * 2024-01-05 2025-07-10 Eugit Therapeutics, Inc. Targeting payloads
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2016274633B2 (en) 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
US11299708B2 (en) 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US20180028566A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
EP3645050A4 (en) 2017-06-25 2021-08-11 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3743081A4 (en) 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
AU2019344300A1 (en) * 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
US12084500B2 (en) * 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
PL4269444T3 (pl) 2020-08-14 2025-01-13 GammaDelta Therapeutics Limited Wieloswoiste przeciwciała anty-tcr zmienne delta 1
AU2022224391A1 (en) 2021-02-17 2023-08-24 Gammadelta Therapeutics Ltd Anti-tcr delta variable 1 antibodies

Also Published As

Publication number Publication date
EP4269446B1 (en) 2024-06-26
EP4265643B1 (en) 2024-06-26
JP7847579B2 (ja) 2026-04-17
AU2021323512A1 (en) 2023-04-13
PT4269444T (pt) 2024-09-05
EP4010082A1 (en) 2022-06-15
LT4010082T (lt) 2023-03-10
ES2993071T3 (en) 2024-12-20
DK4269444T3 (en) 2024-08-19
EP4265643A2 (en) 2023-10-25
EP4265642B1 (en) 2024-06-26
FI4010082T3 (fi) 2023-04-04
EP4218932A2 (en) 2023-08-02
EP4269446A3 (en) 2024-02-14
PL4269444T3 (pl) 2025-01-13
PL4010082T5 (pl) 2026-03-09
DK4010082T5 (da) 2024-08-05
CA3188682A1 (en) 2022-02-17
EP4265643A3 (en) 2024-02-14
EP4010082B2 (en) 2025-12-31
PL4010082T3 (pl) 2023-05-29
CO2023003009A2 (es) 2023-03-17
SI4269444T1 (sl) 2024-10-30
EP4265642A3 (en) 2024-02-14
EP4010082B1 (en) 2023-01-25
FI4269444T3 (fi) 2024-09-20
DK4269444T5 (da) 2024-08-26
ES2943063T3 (es) 2023-06-08
EP4218932A3 (en) 2023-09-27
LT4269444T (lt) 2024-09-25
EP4265642A2 (en) 2023-10-25
EP4269444A3 (en) 2024-02-14
WO2022034562A1 (en) 2022-02-17
DK4010082T3 (da) 2023-04-03
KR20230083267A (ko) 2023-06-09
EP4269445B1 (en) 2024-06-26
SI4010082T1 (sl) 2023-04-28
DK4010082T4 (en) 2026-02-16
EP4269445A2 (en) 2023-11-01
BR112023002741A2 (pt) 2023-10-10
EP4010082B9 (en) 2026-03-04
EP4269444B1 (en) 2024-06-26
MX2023001728A (es) 2023-04-20
IL300517A (en) 2023-04-01
EP4269444A2 (en) 2023-11-01
EP4269446A2 (en) 2023-11-01
EP4269445A3 (en) 2024-02-14
JP2023537534A (ja) 2023-09-01
CN116209456A (zh) 2023-06-02
PT4010082T (pt) 2023-04-26

Similar Documents

Publication Publication Date Title
FI4010082T4 (fi) Multispesifisiä vaihtelevan tcr-deltaketjun 1 vastaisia vasta-aineita
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
FI3487882T3 (fi) Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja
JP2020114241A5 (https=)
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
FI3592769T3 (fi) Vasta-aineita PD-L1:tä vastaan
RU2010108525A (ru) Антитела человека с высокой аффинностью к фактору роста нервов человека
RU2012119788A (ru) Связывающие il-1 белки
HRP20131085T1 (hr) Uporaba antagonistiäśkih anti-cd40 monoklonskih antitijela
FI3618928T3 (fi) Anti-sortiliini-vasta-aineita ja menetelmiä niiden käyttämiseksi
RU2016100892A (ru) Антитела против tweakr и их применение
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
JP2014509510A5 (https=)
JP2014519317A5 (https=)
RU2018143977A (ru) Антитела анти-tnfrsf25
JP2022515152A5 (https=)
JP2022516071A5 (https=)
RU2018138053A (ru) Гуманизированные антитела против базигина и их применение
WO2020257789A3 (en) Anti-tim-3 antibodies
CA3114467A1 (en) Anti pd-l1 antibody and use thereof
JP2018502068A5 (https=)
RU2014108815A (ru) Новые антитела к фосфорилхолину
JPWO2022044573A5 (https=)
IL277899B2 (en) Methods and preparations for treating yellow fever
RU2021119682A (ru) Антитела против клаудина и их применение